Viking Therapeutics Inc. (VKTX) NASDAQ

$4.01 -0.08 (-1.96%)

Market Cap: $307.52M

As of 11/25/22 01:00 PM EST. Market closed.

(VKTX)

Viking Therapeutics Inc. (VKTX) NASDAQ

$4.01 -0.08 (-1.96%)

Market Cap: $307.52M

As of 11/25/22 01:00 PM EST. Market closed.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical ... read more

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Brian Lian
Full Time Employees
19
CEO Compensation (Base)
$485,000
CEO Compensation (Total)
$1.40M
URL
Address
12340 El Camino Real Ste 250, California, San Diego, 92130-3093.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Brian Lian
Full Time Employees
19
CEO Compensation (Base)
$485,000
CEO Compensation (Total)
$1.40M
Address
12340 El Camino Real Ste 250, California, San Diego, 92130-3093.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$4.07
Previous Close
$4.09
Days Range
$3.98 - $4.08
52 week range
$2.02 - $5.55
Volume
161,715
Avg. Volume (30 days)
903,585
Market Cap
$307.52M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
76,688,478
Open
$4.07
Previous Close
$4.09
Days Range
$3.98 - $4.08
52 week range
$2.02 - $5.55
Volume
161,715
Avg. Volume (30 days)
903,585
Market Cap
$307.52M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
76,688,478

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR VIKING THERAPEUTICS INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
FOEHR MATTHEW W Director May 02, 2022 Buy $2.47 45,000 111,195 111,250 May 03, 2022, 04:12 PM
Mancini Marianna Chief Operating Officer Jan 15, 2022 Option Exercise $4.24 827 3,506 238,695 Feb 11, 2022, 06:34 PM
ZANTE GREG Chief Financial Officer Jan 04, 2022 Option Exercise $4.62 8,835 40,818 136,304 Jan 05, 2022, 07:13 PM
ZANTE GREG Chief Financial Officer Jan 03, 2022 Option Exercise $4.88 3,097 15,113 91,806 Jan 05, 2022, 07:13 PM
Mancini Marianna Chief Operating Officer Jan 04, 2022 Option Exercise $4.62 11,845 54,724 239,522 Jan 05, 2022, 07:12 PM
Mancini Marianna Chief Operating Officer Jan 03, 2022 Option Exercise $4.88 3,919 19,125 174,034 Jan 05, 2022, 07:12 PM
Lian Brian President & CEO Jan 03, 2022 Option Exercise $4.88 36,319 177,237 1,889,785 Jan 05, 2022, 07:12 PM
Lian Brian President & CEO Jan 04, 2022 Option Exercise $4.62 26,432 122,116 2,036,686 Jan 05, 2022, 07:12 PM
Lian Brian President & CEO Sep 28, 2021 Option Exercise $6.50 27,750 180,375 1,924,807 Sep 30, 2021, 05:48 PM
Mancini Marianna Chief Operating Officer Sep 28, 2021 Option Exercise $6.50 2,839 18,454 177,535 Sep 30, 2021, 05:45 PM
ZANTE GREG Chief Financial Officer Sep 28, 2021 Option Exercise $6.50 2,306 14,989 94,485 Sep 30, 2021, 05:43 PM
FOEHR MATTHEW W Director Jun 10, 2021 Buy $5.69 20,000 113,800 66,250 Jun 10, 2021, 04:57 PM
FOEHR MATTHEW W Director Mar 22, 2021 Option Exercise $1.50 20,000 30,000 46,250 Mar 25, 2021, 09:30 PM
ZANTE GREG Chief Financial Officer Jan 19, 2021 Option Exercise $6.68 808 5,397 89,751 Jan 19, 2021, 06:25 PM
Mancini Marianna Chief Operating Officer Jan 19, 2021 Option Exercise $6.68 994 6,640 169,952 Jan 19, 2021, 06:23 PM
Mancini Marianna Chief Operating Officer Jan 15, 2021 Option Exercise $6.48 686 4,445 170,946 Jan 19, 2021, 06:23 PM
MORNEAU MICHAEL VP, Finance and Administration Jan 19, 2021 Option Exercise $6.68 1,685 11,256 116,062 Jan 19, 2021, 06:21 PM
Lian Brian President & CEO Jan 19, 2021 Option Exercise $6.68 5,611 37,481 1,894,181 Jan 19, 2021, 06:19 PM
Lian Brian President & CEO Jan 04, 2021 Option Exercise $5.80 16,973 98,443 1,899,792 Jan 06, 2021, 04:34 PM
Lian Brian President & CEO Jan 03, 2021 Option Exercise $5.63 31,545 177,598 1,712,432 Jan 06, 2021, 04:34 PM
ZANTE GREG Chief Financial Officer Jan 04, 2021 Option Exercise $5.80 2,787 16,165 90,559 Jan 06, 2021, 04:28 PM
Mancini Marianna Chief Operating Officer Jan 04, 2021 Option Exercise $5.80 2,773 16,083 171,632 Jan 06, 2021, 04:26 PM
MORNEAU MICHAEL VP, Finance and Administration Jan 04, 2021 Option Exercise $5.80 2,739 15,886 117,747 Jan 06, 2021, 12:00 AM
MORNEAU MICHAEL VP, Finance and Administration Sep 15, 2020 Option Exercise $6.25 1,557 9,731 97,873 Sep 16, 2020, 05:21 PM
Lian Brian President & CEO Sep 15, 2020 Option Exercise $6.25 19,192 119,950 1,742,363 Sep 16, 2020, 05:18 PM
LIGAND PHARMACEUTICALS INC 10% Owner Aug 26, 2020 Sale $8.11 148,700 1,205,660 5,819,383 Aug 28, 2020, 05:11 PM
LIGAND PHARMACEUTICALS INC 10% Owner Aug 26, 2020 Sale $8.11 94,488 766,109 5,819,383 Aug 27, 2020, 07:06 PM
LIGAND PHARMACEUTICALS INC 10% Owner Aug 25, 2020 Sale $8.02 70,000 561,575 5,968,083 Aug 27, 2020, 07:06 PM
FOEHR MATTHEW W Director Jun 30, 2020 Sale $7.35 13,000 95,550 26,250 Jun 30, 2020, 05:54 PM
Lian Brian President & CEO Jan 19, 2020 Option Exercise $7.18 3,195 22,940 1,704,312 Jan 21, 2020, 05:39 PM
MORNEAU MICHAEL VP, Finance and Administration Jan 19, 2020 Option Exercise $7.18 2,044 14,676 92,840 Jan 21, 2020, 05:35 PM
Lian Brian President & CEO Jan 03, 2020 Option Exercise $7.77 6,782 52,696 1,707,507 Jan 03, 2020, 08:01 PM
MORNEAU MICHAEL VP, Finance and Administration Jan 19, 2019 Option Exercise $8.78 2,044 17,946 91,991 Jan 22, 2019, 07:13 PM
Lian Brian President & CEO Jan 19, 2019 Option Exercise $8.78 4,333 38,044 1,560,152 Jan 22, 2019, 07:13 PM
LIGAND PHARMACEUTICALS INC 10% Owner Sep 25, 2018 Sale $19.15 262,881 5,034,250 6,038,083 Sep 27, 2018, 09:25 PM
SINGLETON J MATTHEW Director May 31, 2018 Buy $9.82 9,500 93,261 9,500 May 31, 2018, 07:04 PM
MORNEAU MICHAEL VP, Finance and Administration May 31, 2018 Sale $9.25 21,551 199,347 94,035 May 31, 2018, 07:03 PM
Rowland Charles A Jr Director May 29, 2018 Buy $5.16 30,000 154,800 30,000 May 31, 2018, 07:02 PM
Webster Stephen W Director May 29, 2018 Buy $5.21 8,000 41,712 8,000 May 31, 2018, 06:59 PM
MACARTNEY LAWSON Director May 29, 2018 Buy $5.22 47,965 250,329 47,965 May 31, 2018, 06:57 PM
MORNEAU MICHAEL VP, Finance and Administration May 04, 2018 Option Exercise $4.22 7,616 32,140 94,035 May 08, 2018, 08:37 PM
Lian Brian President & CEO May 04, 2018 Option Exercise $4.22 10,086 42,563 1,483,012 May 08, 2018, 08:37 PM
MORNEAU MICHAEL Chief Financial Officer May 04, 2017 Option Exercise $1.34 8,192 10,977 80,604 May 05, 2017, 06:25 PM
FOEHR MATTHEW W Director Nov 15, 2016 Buy $1.21 13,000 15,678 39,250 Nov 15, 2016, 04:34 PM
Hanley Rochelle Chief Medical Officer May 04, 2016 Option Exercise $1.31 10,595 13,879 160,836 May 05, 2016, 05:36 PM
LIGAND PHARMACEUTICALS INC 10% Owner Apr 13, 2016 Option Exercise $1.25 960,000 1,200,000 6,300,964 Apr 15, 2016, 05:19 PM
FOEHR MATTHEW W Director Apr 13, 2016 Buy $1.24 20,000 24,800 26,250 Apr 13, 2016, 06:17 PM
Lian Brian President & CEO May 04, 2015 Option Exercise $9.49 16,346 155,124 1,453,098 May 06, 2015, 08:20 PM
Dinerman Michael Chief Operating Officer May 04, 2015 Option Exercise $9.49 8,724 82,791 694,116 May 06, 2015, 08:19 PM
MORNEAU MICHAEL Chief Financial Officer May 04, 2015 Option Exercise $9.49 10,404 98,734 77,404 May 06, 2015, 07:20 PM
Hanley Rochelle Chief Medical Officer May 04, 2015 Option Exercise $9.49 7,308 69,353 168,855 May 06, 2015, 07:18 PM
FOEHR MATTHEW W Director May 04, 2015 Buy $8.00 6,250 50,000 6,250 May 05, 2015, 01:47 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
FOEHR MATTHEW W Director 05/02/2022 111,195
Mancini Marianna Chief Operating Officer 01/15/2022 3,506
ZANTE GREG Chief Financial Officer 01/04/2022 40,818
ZANTE GREG Chief Financial Officer 01/03/2022 15,113
Mancini Marianna Chief Operating Officer 01/04/2022 54,724
Mancini Marianna Chief Operating Officer 01/03/2022 19,125
Lian Brian President & CEO 01/03/2022 177,237
Lian Brian President & CEO 01/04/2022 122,116
Lian Brian President & CEO 09/28/2021 180,375
Mancini Marianna Chief Operating Officer 09/28/2021 18,454
ZANTE GREG Chief Financial Officer 09/28/2021 14,989
FOEHR MATTHEW W Director 06/10/2021 113,800
FOEHR MATTHEW W Director 03/22/2021 30,000
ZANTE GREG Chief Financial Officer 01/19/2021 5,397
Mancini Marianna Chief Operating Officer 01/19/2021 6,640
Mancini Marianna Chief Operating Officer 01/15/2021 4,445
MORNEAU MICHAEL VP, Finance and Administration 01/19/2021 11,256
Lian Brian President & CEO 01/19/2021 37,481
Lian Brian President & CEO 01/04/2021 98,443
Lian Brian President & CEO 01/03/2021 177,598
ZANTE GREG Chief Financial Officer 01/04/2021 16,165
Mancini Marianna Chief Operating Officer 01/04/2021 16,083
MORNEAU MICHAEL VP, Finance and Administration 01/04/2021 15,886
MORNEAU MICHAEL VP, Finance and Administration 09/15/2020 9,731
Lian Brian President & CEO 09/15/2020 119,950
LIGAND PHARMACEUTICALS INC 10% Owner 08/26/2020 1,205,660
LIGAND PHARMACEUTICALS INC 10% Owner 08/26/2020 766,109
LIGAND PHARMACEUTICALS INC 10% Owner 08/25/2020 561,575
FOEHR MATTHEW W Director 06/30/2020 95,550
Lian Brian President & CEO 01/19/2020 22,940
MORNEAU MICHAEL VP, Finance and Administration 01/19/2020 14,676
Lian Brian President & CEO 01/03/2020 52,696
MORNEAU MICHAEL VP, Finance and Administration 01/19/2019 17,946
Lian Brian President & CEO 01/19/2019 38,044
LIGAND PHARMACEUTICALS INC 10% Owner 09/25/2018 5,034,250
SINGLETON J MATTHEW Director 05/31/2018 93,261
MORNEAU MICHAEL VP, Finance and Administration 05/31/2018 199,347
Rowland Charles A Jr Director 05/29/2018 154,800
Webster Stephen W Director 05/29/2018 41,712
MACARTNEY LAWSON Director 05/29/2018 250,329
MORNEAU MICHAEL VP, Finance and Administration 05/04/2018 32,140
Lian Brian President & CEO 05/04/2018 42,563
MORNEAU MICHAEL Chief Financial Officer 05/04/2017 10,977
FOEHR MATTHEW W Director 11/15/2016 15,678
Hanley Rochelle Chief Medical Officer 05/04/2016 13,879
LIGAND PHARMACEUTICALS INC 10% Owner 04/13/2016 1,200,000
FOEHR MATTHEW W Director 04/13/2016 24,800
Lian Brian President & CEO 05/04/2015 155,124
Dinerman Michael Chief Operating Officer 05/04/2015 82,791
MORNEAU MICHAEL Chief Financial Officer 05/04/2015 98,734
Hanley Rochelle Chief Medical Officer 05/04/2015 69,353
FOEHR MATTHEW W Director 05/04/2015 50,000
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2022
06/30/2022
-0.27%
1Q
09/30/2022
03/31/2022
-0.64%
2Q
09/30/2022
12/31/2021
-0.36%
3Q
09/30/2022
09/30/2021
0.01%
4Q
09/30/2022
06/30/2021
0.75%
5Q
09/30/2022
03/31/2021
2.85%
6Q
09/30/2022
12/31/2020
5.95%
7Q
09/30/2022
09/30/2020
6.10%
8Q
09/30/2022
06/30/2020
6.21%
9Q
09/30/2022
03/31/2020
6.30%
10Q
09/30/2022
12/31/2019
6.89%
11Q
09/30/2022
09/30/2019
6.97%
12Q
09/30/2022
06/30/2019
7.07%
13Q
09/30/2022
03/31/2019
7.19%
14Q
09/30/2022
12/31/2018
33.58%
15Q
Load More

Period of Report: 09/30/2022

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
06/30/2022
-0.27%
1Q
03/31/2022
-0.64%
2Q
12/31/2021
-0.36%
3Q
09/30/2021
0.01%
4Q
06/30/2021
0.75%
5Q
03/31/2021
2.85%
6Q
12/31/2020
5.95%
7Q
09/30/2020
6.10%
8Q
06/30/2020
6.21%
9Q
03/31/2020
6.30%
10Q
12/31/2019
6.89%
11Q
09/30/2019
6.97%
12Q
06/30/2019
7.07%
13Q
03/31/2019
7.19%
14Q
12/31/2018
33.58%
15Q
Load More